Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma

Abstract The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dana S. Neel, Trever G. Bivona
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Acceso en línea:https://doaj.org/article/0533102711904302b1f2fc1f1df3168a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!